

REMARKS

As a preliminary matter, Applicants thank the Examiner for discussing the instant application with Applicants' attorney in an interview on September 30, 2009.

Prior to entry of the instant supplemental amendment, claims 73 and 75-101 were pending in the application. *For purposes of expedited prosecution*, claims 73, 76-77 and 98 have been amended to clarify the claimed invention as discussed during the Examiner interview. In particular, the claims have been amended to clarify an essential feature of the invention which is administration of a GnRH agonist during the luteal phase in an amount and for a time sufficient to support the luteal phase as a means of treating infertility. Luteal phase support is commenced after ovulation in a female, either spontaneous or stimulated with chemical agents. In embodiments where ovulation is stimulated with a chemical agent, induction is a separate step (i.e. a distinct administration step) from support of the luteal phase and can be accomplished by administering a GnRH agonist or another of the agents recited in the specification. The GnRH agonist can be the same or different from that used to support the luteal phase, however, administration to stimulate ovulation is a distinct step, i.e. agent administered early in the cycle, from support of luteal phase, i.e., administration beginning within the first three days following ovulation. Claim 75 has been cancelled. New claims 104-106 have been added. Accordingly, upon entry of the instant amendment, claims 73, 76-101 and 104-106 will remain pending. No new matter has been added.

Support for the amended claim may be found throughout the specification and claims as originally filed. In particular, support for the amendment to claim 73 can be found at least on page 16, lines 12-23. Support for the amendment to claim 76 can be found at least on page 10, lines 6-9, and page 17, lines 9-10. Support for the amendment to claim 98 and for new claims 104-106 can be found at least on page 16, lines 22-23. Support for new claims 104-106 can also be found at least in Examples 1-2 and Tables 1-3 of the specification. Accordingly, Applicants respectfully request that the foregoing amendment be entered. Applicants reserve the right to pursue the claims as originally filed in this or a separate application(s).

The foregoing claim amendments have been made solely for the purpose of expediting prosecution of the present application and should in no way be construed as acquiescence to any of the Examiner's rejections in any Office Action issued in the present application. Applicants

reserve the right to pursue the subject matter of the present claims prior to being amended herein in this application or in another related application.

In view of the above amendment, Applicants believe the pending application is in condition for allowance. If a telephone conversation with Applicants' attorney would help expedite the prosecution of the above-identified application, the Examiner is urged to call Applicants' attorney at (617) 227-7400.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. KZY-001US.

Dated: October 23, 2009

Respectfully submitted,

Electronic signature: /Debra J. Milasincic, Esq./
Debra J. Milasincic, Esq.

Registration No.: 46,931

LAHIVE & COCKFIELD, LLP

One Post Office Square
Boston, Massachusetts 02109-2127
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicant